| Greenwich LifeSciences Provides Global Update on FLAMINGO-01 |
STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following global update on FLAMINGO-01. Flamingo-01 Progress to Date & Future Plans The Company recently confirmed that the preliminary HLA prevalence, safety, and immune response data in FLAMINGO-01 patients is trending as expected in both HLA-A*02 and non-HLA-A*02 arms. |
globenewswire.com |
2025-04-03 12:00:00 |
Czytaj oryginał (ang.) |
| Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial |
STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label immune response data. |
globenewswire.com |
2025-04-02 10:00:00 |
Czytaj oryginał (ang.) |
| Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026 |
STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to March 31, 2026 which is approximately 66 months from date of the Company's IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless otherwise modified by the Board of Directors. After March 31, 2026, the quantity of these locked-up shares that can be sold daily and over various periods of time will be restricted unless otherwise modified by the Board of Directors. |
globenewswire.com |
2025-03-27 08:00:00 |
Czytaj oryginał (ang.) |
| Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01 |
STAFFORD, Texas, March 17, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label safety data. |
globenewswire.com |
2025-03-17 08:45:00 |
Czytaj oryginał (ang.) |
| Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01 |
STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label HLA data. |
globenewswire.com |
2025-02-10 08:00:00 |
Czytaj oryginał (ang.) |
| Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe |
STAFFORD, Texas, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the expansion of the clinical trial into Europe. |
globenewswire.com |
2025-01-29 08:00:00 |
Czytaj oryginał (ang.) |
| Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland |
STAFFORD, Texas, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the activation of clinical sites in Poland. |
globenewswire.com |
2025-01-27 08:00:00 |
Czytaj oryginał (ang.) |
| Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01 |
STAFFORD, Texas, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of new clinical sites in the US. |
globenewswire.com |
2025-01-23 08:00:00 |
Czytaj oryginał (ang.) |
| Greenwich LifeSciences Provides Update on Commercial Manufacturing |
STAFFORD, Texas, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the commercial manufacturing of GP2. |
globenewswire.com |
2025-01-22 08:00:00 |
Czytaj oryginał (ang.) |
| Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI) |
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) concerning the Company and its directors' and officers' possible violations of state laws. If you own Greenwich LifeSciences stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 358, New Yo. |
businesswire.com |
2025-01-17 10:20:00 |
Czytaj oryginał (ang.) |
| Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01 |
STAFFORD, Texas, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of clinical sites in Germany. |
globenewswire.com |
2025-01-14 08:15:00 |
Czytaj oryginał (ang.) |
| Greenwich LifeSciences Partners with GIM in Italy |
STAFFORD, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced its partnership with clinical sites in Italy. |
globenewswire.com |
2024-11-26 08:00:00 |
Czytaj oryginał (ang.) |
| Greenwich LifeSciences Provides Update on Corporate Events |
STAFFORD, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on corporate events. |
globenewswire.com |
2024-11-18 08:00:00 |
Czytaj oryginał (ang.) |
| Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain |
STAFFORD, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update of the expansion of clinical sites into Spain. |
globenewswire.com |
2024-08-01 10:00:00 |
Czytaj oryginał (ang.) |
| Greenwich LifeSciences: Halting Of Breast Cancer Recurrence With GLSI-100 |
Greenwich LifeSciences, Inc. approaches enrollment completion for the phase 3 Flamingo-01 study, using GLSI-100 for the treatment of patients with HER2/neu positive breast cancer, with full enrollment expected by the end of 2024. A prior phase 2b study indicated that patients, given GLSI-100 for HER2/neu positive breast cancer, were able to achieve a 100% recurrence free rate. The global breast cancer market size is expected to be worth $49.2 billion by 2032. |
seekingalpha.com |
2024-06-26 18:05:02 |
Czytaj oryginał (ang.) |
| Greenwich LifeSciences Set to Join Russell 2000 Index Again |
STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it is set to join the Russell 2000 and Russell 3000 Indexes at the conclusion of the Russell indexes annual reconstitution, effective after the US markets open on July 1, 2024, according to a list of additions updated as of June 21, 2024. |
globenewswire.com |
2024-06-26 11:33:00 |
Czytaj oryginał (ang.) |
| Greenwich LifeSciences Announces $2.5 Million Private Placement |
STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it has entered into a securities purchase agreement with its Chief Executive Officer, Snehal Patel, for the purchase and sale of 174,825 shares of its common stock at a purchase price of $14.30 per share in a private placement. The closing of the private placement is expected to occur on or about June 18, 2024, subject to the satisfaction of customary closing conditions. |
globenewswire.com |
2024-06-14 10:00:00 |
Czytaj oryginał (ang.) |
| Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025 |
STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to June 30, 2025 which is approximately 57 months from date of the Company's IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless otherwise modified by the Board of Directors. |
globenewswire.com |
2024-03-13 08:00:00 |
Czytaj oryginał (ang.) |
| Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe |
STAFFORD, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of the first clinical sites in Europe in collaboration with GEICAM in Spain. |
globenewswire.com |
2024-03-12 08:00:00 |
Czytaj oryginał (ang.) |
| Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries |
STAFFORD, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the expansion of the clinical trial into Europe. |
globenewswire.com |
2024-02-27 08:00:00 |
Czytaj oryginał (ang.) |
| Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators |
STAFFORD, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on the expansion of the clinical trial into Europe. |
globenewswire.com |
2024-02-22 08:00:00 |
Czytaj oryginał (ang.) |
| Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01 |
STAFFORD, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on the Phase III clinical trial, Flamingo-01. |
globenewswire.com |
2024-02-14 08:00:00 |
Czytaj oryginał (ang.) |
| Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024 |
STAFFORD, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to December 31, 2024 which is approximately 51 months from date of the Company's IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless otherwise modified by the Board of Directors. |
globenewswire.com |
2023-11-21 08:00:00 |
Czytaj oryginał (ang.) |
| TOPS, SURG: The Top 5 Short Squeeze Stocks This Week |
Source: g0d4ather / Shutterstock.com Short squeeze stocks are still popular with speculative traders and that has us going over the top ones to keep an eye on this week! Luckily, Fintel has traders covered with its Short Squeeze Leaderboard. |
investorplace.com |
2022-10-10 15:55:33 |
Czytaj oryginał (ang.) |
| GLSI, APRN: The Top 5 Short Squeeze Stocks to Watch This Week |
Source: g0d4ather / Shutterstock.com Investors are still interested in short squeeze stocks and we've got them covered with the ones to watch this week! Fintel is offering up a list of the short squeeze stocks to watch with its Short Squeeze Leaderboard. |
investorplace.com |
2022-10-03 15:08:58 |
Czytaj oryginał (ang.) |
| NRBO, FAZE: The Top 5 Short Squeeze Stocks to Watch This Week |
Source: Alextype/Shutterstock.com Traders continue to show interest in short squeeze stocks this week as they seek out likely targets to push higher. This has us checking out Fintel's Short Squeeze Leaderboard. |
investorplace.com |
2022-09-19 15:59:36 |
Czytaj oryginał (ang.) |
| ATHX, PETS: The Top 5 Short Squeeze Stocks to Watch This Week |
Source: g0d4ather / Shutterstock.com We're starting off another week with a deep dive into the short squeeze stocks to watch! Short squeeze stocks have been popular with traders in recent months as they search for the next big breakout. |
investorplace.com |
2022-09-12 15:37:45 |
Czytaj oryginał (ang.) |
| Greenwich LifeSciences: Persevering CEO And Interesting Data |
Greenwich LifeSciences, Inc. is a one-man, one-asset shop. The asset, GP2, has produced excellent breast cancer data. |
seekingalpha.com |
2022-09-06 21:40:54 |
Czytaj oryginał (ang.) |
| 7 Short-Term Stocks to Buy for a Quick Profit |
While most people don't like to see red ink in their investment portfolios, at the same time, that negative print comes from volatility — and volatility in either direction presents opportunities for short-term stocks to buy for a quick profit. Here, the narrative isn't necessarily about finding a great company on discount. |
investorplace.com |
2022-08-08 20:32:19 |
Czytaj oryginał (ang.) |
| Here's Why Greenwich Lifesciences Shares Are Popping Off Today |
Greenwich Lifesciences Inc (NASDAQ: GLSI) shares are trading higher by 32.95% to $11.46 Tuesday afternoon after the FDA removed the clinical hold on the company's Flamingo-01 Phase 3 trial of GP2. Greenwich Lifesciences says through discussions with the FDA and testing of GP2 in the. |
benzinga.com |
2022-07-12 17:18:03 |
Czytaj oryginał (ang.) |
| Why Is Greenwich Lifesciences (GLSI) Stock Up Today? |
Greenwich Lifesciences (GLSI) stock is heading higher on Tuesday after the FDA lifted a hold on a Phase III clinical trial. The post Why Is Greenwich Lifesciences (GLSI) Stock Up Today? |
investorplace.com |
2022-07-12 14:51:01 |
Czytaj oryginał (ang.) |